Meeting
2015 ASCO Annual Meeting
PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.
Authors
Patricia Villagrasa
SOLTI Breast Cancer Research Group, Barcelona, Spain
Patricia Villagrasa , Xavier Gonzalez , Mafalda Oliveira , Josep Vazquez , Lorena De La Pena , Marta Llobet-Canela , Aleix Prat , Eva Ciruelos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
2014-005006-38
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS642)
DOI
10.1200/jco.2015.33.15_suppl.tps642
Abstract #
TPS642
Poster Bd #
122b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab ﴾HR+ with or without letrozole﴿ in trastuzumab‐pretreated, postmenopausal patients with HER2‐positive metastatic breast cancer.
First Author: Patricia Villagrasa
Poster
2021 ASCO Annual Meeting
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
First Author: Jian Zhang
Poster
2021 ASCO Annual Meeting
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).
First Author: Tom Stinchcombe
Poster
2019 ASCO Annual Meeting
Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.
First Author: Laura Spring